Blog - Page 923 of 5700 - QualityStocks

FridayJul 29, 2022 10:30 am

iGaming Legalized in Ontario, Golden Matrix Group Inc. (NASDAQ: GMGI) Positioned to Benefit from Relaxed Legislation

Canadian province of Ontario recently legalized iGaming, other provinces expected to follow iGaming industry expected to reach 153.6 billion by 2030 at CAGR of 11.7% from 2022 to 2030 GMGI offers highly modular, turnkey, and white label gaming solutions for growing B2B customer base Recently released financial results reveal 15 consecutive profitable quarters, 221% Q2-2022 growth The province of Ontario in Canada has recently joined South Africa, Japan, and many European Union countries in legalizing iGaming (https://ibn.fm/65kyx). Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, is positioned to benefit from relaxed…

FridayJul 29, 2022 9:00 am

From West to East, EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Stretching its RNG Footprint Across Canada

Formed just two years ago, EverGen began with the acquisition of two waste-to-energy facilities in British Columbia In the last two months, EverGen has expanded its Canadian presence, making acquisitions of facilities and projects in Alberta and Ontario The company is targeting RNG production in excess of 1 million gigajoules annually Have garbage, will travel. That could easily be the mantra of Chase Edgelow and Mischa Zajtmann, the founders of EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a company working on disrupting Canada’s energy industry with its renewable natural gas (“RNG”) infrastructure platform. As recently as May, EverGen described itself as…

FridayJul 29, 2022 8:45 am

Friendable Inc. (FDBL) Announces Largest Contest to Date, with a $1,000 Cash Prize for Each Winner in Five Music Genres

Friendable announces the “Song of the Summer” contest through Artist Republik, with artist submissions accepted through July 31, 2022 One winner in each genre - Hip Hop/Rap, Rock/Punk/Metal, Latin, EDM, and Pop – will be voted on by fans to win $1,000, a total of $5,000 across all genres Friendable’s acquisition of Artist Republik and FeaturedX in January 2022 has expanded the Fan Pass Live offering to create a 360-degree suite of services for independent artists to produce, distribute, and market their music without label control Friendable (OTC: FDBL), a mobile technology and marketing company, recently announced its “Song of…

ThursdayJul 28, 2022 1:45 pm

DPCM Capital Inc. (NYSE: XPOA) and D-Wave Systems Inc. Highlight Unique Bonus Pool Structure for Up to 5 Million Shares to be Allocated Pro-Rata to Non-Redeeming DPCM Capital Stockholders

DPCM Capital stockholders have been offered an innovative bonus pool structure that incentivizes stockholders and reduces their cost basis per share by as much as 31% The bonus pool is highlighted ahead of the July 29, 2022 redemption deadline to incentivize ongoing retention and long-term investment in D-Wave by DPCM Capital stockholders DPCM Capital (NYSE: XPOA), a special purpose acquisition company, and D-Wave Systems Inc., a leader in quantum computing systems, software, and services, have highlighted an innovative bonus pool structure for DCPM Capital stockholders in advance of the deadline for redemption at 5:00 p.m. EDT on July 29, 2022.…

ThursdayJul 28, 2022 12:21 pm

QualityStocksNewsBreaks – QSAM Biosciences Inc. (QSAM) Targeting Significant Unmet Medical Need with CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “QSAM is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical technology: CycloSam(R),” a recent article reads.…

ThursdayJul 28, 2022 12:08 pm

QualityStocksNewsBreaks – FuelPositive Corporation’s (TSX.V: NHHH) (OTCQB: NHHHF) Ammonia Production System Designed to Eliminate Supply Chain Dependence, Stabilize Prices

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is driving the message that fossil fuels do not only damage the climate but also make the world economically vulnerable. This comes amid high fertilizer prices and the inherent presence and effects of climate change, factors threatening the rice production industry worldwide. “Carbon emissions are the leading cause of climate change and global warming issues worldwide. The company’s Hydrogen-Ammonia Synthesizer technology provides the means necessary to store green hydrogen as green ammonia that is completely carbon-free. The hydrogen can be removed when needed for use in fuel cells and other applications based on pure hydrogen…

ThursdayJul 28, 2022 11:57 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Dedicating Strategy Toward Acquisition, Creation of Lifesaving Medical Products

Odyssey Health (OTC: ODYY) continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. “Odyssey’s portfolio includes medical device candidates and pharmaceutical products in development that are responsive to conditions such as heart disease, foreign object-induced choking, neurodegenerative disorders, and brain concussion injuries. One drug product designed to treat mild traumatic injury within the first few minutes after an incident is advancing in a phase 1 clinical human trial following on preclinical lab animal tests that provided encouraging data, CEO Michael Redmond said in a June interview,” a recent article reads. “No U.S. Food and…

ThursdayJul 28, 2022 11:15 am

Cub Crafters Inc. Helps Recreational Travelers Take Flight with Classic Piper Cub-inspired Planes

Commercial airlines have seen a resurgence of air travel demand this year following two years of COVID restrictions that kept most people close to home, but many airlines found themselves overwhelmed by the crush of travelers and capped ticket availability Yakima, Washington based CubCrafters Inc. designs, builds, and tests unique light aircraft for those who want to fly themselves The company’s array of aircraft are inspired by the classic Piper PA-18 Super Cub and include a variety of the company’s own Cub-derivative, newly manufactured designs The light and ultralight aircraft market is expected to grow by the end of the…

ThursdayJul 28, 2022 10:53 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation. To view the live presentation, visit https://ibn.fm/ghBjR To view…

ThursdayJul 28, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated…

Site Search

Company Search